The Manufacturers Life Insurance Company Cuts Position in Sanofi $SNY

The Manufacturers Life Insurance Company decreased its position in Sanofi (NASDAQ:SNY) by 58.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,516 shares of the company’s stock after selling 33,713 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Sanofi were worth $1,133,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of SNY. Brighton Jones LLC raised its stake in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after purchasing an additional 1,869 shares in the last quarter. AQR Capital Management LLC lifted its position in Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after purchasing an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Sanofi by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after buying an additional 752 shares in the last quarter. Sivia Capital Partners LLC grew its stake in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after buying an additional 347 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Sanofi by 36.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock worth $159,000 after buying an additional 875 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Price Performance

SNY stock opened at $43.56 on Wednesday. The stock has a market cap of $105.61 billion, a PE ratio of 22.81, a P/E/G ratio of 1.08 and a beta of 0.35. Sanofi has a 12 month low of $40.89 and a 12 month high of $52.68. The company has a 50-day moving average price of $43.34 and a 200 day moving average price of $45.01. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on SNY shares. Weiss Ratings cut shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Morgan Stanley set a $49.00 price objective on Sanofi in a research note on Wednesday, July 8th. Wall Street Zen downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Sunday. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Monday, April 20th. Finally, Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $49.50.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.